Triple-negative breast cancer (TNBC) accounts for 15–20% of all mammary tumors, and it is characterized by estrogen-receptor (ER), progesterone-receptor and HER2-receptor negativity. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.